US-based AutoGenomics, a developer of automated molecular testing solutions has recieved FDA clearance for its Infiniti 2C9-VKORC1 Multiplex assay for Warfarin.
Subscribe to our email newsletter
Fareed Kureshy, president and CEO of AutoGenomics, said: “The FDA recently re- labeled warfarin stating that genetic testing may help optimize the use of the drug and lower the risk of bleeding complications. Several of our customers are awaiting such clearance to implement testing in their practice.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.